ClinicalTrials.gg
RecruitingNCT07241546Updated Oct 1, 2026

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

A Phase 2 interventional study of ARO-RAGE and Placebo in Asthma, sponsored by Arrowhead Pharmaceuticals. Recruiting at 6 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 1, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 428 studies in Asthma with a site in Canada — 41 open to participants now, 56 under way, 11 of them phase 3. Asthma · Canada.

Planned enrollment
252nd of 366
36 · median 108
Started
2026
with 12 others
Phase 2
98 of 428
4 open now
Primary completion
2027-12
later than 38 of 55 live
Registered
418th of 428
by date

Among the 428 studies in Asthma with a site in Canada, this one is the 252nd largest by planned enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2026, is one of 98 in phase 2, reaches primary completion later than 38 of the 55 other live ones, and was the 418th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

41 of the 428 studies in Asthma with a site in Canada are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 428 studies in Asthma with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically stable, mild atopic asthma ( ≥70% predicted)
  • Established allergy confirmed by positive skin prick test at screening
  • Willing and able to perform lung function tests and other study-related procedures
  • Participants of must consent to use a method of highly-effective in addition to a condom during the study and for at least 90 days following the end of study or last product administration, whichever is later

Exclusion criteria

Exclusion Criteria:

  • Concomitant diagnosis of a pulmonary disease other than asthma
  • Use of , immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
  • History or current medical condition contraindicating methacholine challenge

Note: Additional inclusion/exclusion criteria may apply per protocol.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    ARO-RAGE

    ARO-RAGE inhalation

    Drug: ARO-RAGE

  • Placebo comparator
    Placebo

    Normal saline (0.9%)

    Drug: Placebo

Interventions

  • DrugARO-RAGE

    Inhalation of nebulized solution

  • DrugPlacebo

    Calculated volume to match active treatment by inhalation of nebulized solution

06

What researchers measure

Primary outcomes

  1. Change from Baseline Over Time in Maximum Area of Reactance

    Time frame: Baseline through Day 58

Secondary outcomes

  1. Change from Baseline Over Time in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve

    Time frame: Baseline through Day 58

  2. Change from Baseline Over Time in Maximum Change in Small Airway Reactance

    Time frame: Baseline through Day 58

  3. Number of Participants with Treatment-Emergent Adverse Events

    Time frame: Up to Day 113 (End of Study)

07

Study locations

6 of 6 sites recruiting
  • Research Site 1
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
  • Research Site 2
    Calgary, T2N 4N1, Canada
    Recruiting
  • Research Site 3
    Edmonton, T6G 2G3, Canada
    Recruiting
  • Research Site 5
    Hamilton, L8N 3Z5, Canada
    Recruiting
  • Research Site 6
    Québec, G1V-4G5, Canada
    Recruiting
  • Research Site 4
    Saskatoon, S7M 2W2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 21 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Mar 30, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Research Site 6 · Québec, Canada
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added
    Show site
    • Research Site 6 · Québec, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07241546
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Mar 30, 2026
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Medical Monitor
Contact
ARORAGE-2001@arrowheadpharma.com
626-304-3400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion